The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Learn what scientific research and experts say about the evidence for common home remedies for herpes, including honey, lemon balm, and petroleum jelly.

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

Future Microbiol. 2010;5(1):15-22. The ocular and genital mucosa are key players in regulation of herpes simplex virus (HSV) susceptibility and recurrent disease. Prophylactic and therapeutic ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments ...

Ruvidar(TM) demonstrates higher efficacy in the treatment of Herpes Simplex Virus, Type 1 versus FDA-approved, standard of care treatments Acyclovir and Abreva in a preclinical animal model. In the ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. Germany’s ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ...

BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage ...

The MarketWatch News Department was not involved in the creation of this content. BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical ...